View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 14, 2021updated 11 Jul 2022 2:22pm

NeuroBo to continue Phase II/III Covid drug trial without modifications

The DMC reviewed safety results from 36 Covid-19 patients treated with the company’s oral niclosamide formulation ANA001.

NeuroBo Pharmaceuticals has obtained a recommendation from the independent Data Monitoring Committee (DMC) to continue the Phase II/III clinical trial of its lead drug candidate, ANA001, for treating Covid-19 without any changes.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The move comes after the committee reviewed safety data from 36 subjects who received treatment with ANA001 in the trial.

ANA001 is a proprietary oral formulation of niclosamide, which features antiviral and anti-inflammatory properties.

The two-part multicentre, placebo-controlled double-blind Phase II/III trial is analysing the safety, tolerability and efficacy of ANA001.

Being carried out in the US, both phases of the trial will have subjects suffering with moderate to severe Covid-19 who are in hospital but do not need ventilators.

These subjects will be given ANA001 plus standard-of-care therapy for seven days.

The Phase II trial anticipates recruiting 60 subjects with a primary goal to analyse the safety and tolerability of the drug.

Efficacy measurements such as median time to hospital discharge and pharmacokinetics will be included as secondary goals.

The Phase III segment will enrol several hundred subjects.

Median time to hospital discharge, safety and tolerability will be the primary goals of this phase, while clinical improvement and the requirements and time for rescue treatment will be the secondary goals.

NeuroBo president and CEO Richard Kang said: “The DMC’s recommendation to continue enrolment of the Phase II/III clinical trial, without modification, is an important milestone for our lead drug candidate, ANA001, as a potential treatment for Covid-19.

“We expect to complete the Phase II portion of the trial in the fourth quarter of this year and to achieve a number of value-creating milestones with this programme in the coming months, including initiation of the Phase III of trial.”

In a separate development, TC BioPharm has commenced a Phase I/II trial of its allogeneic gamma-delta T cell product, ImmuniStim, in subjects with Covid-19 in the UK.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena